EN DE
Watch MiMedx Group Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

MiMedx Group Inc (MDXG) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of MiMedx Group Inc stock $7.32, price $3.31, upside +121.1%, quality 69 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

MG MiMedx Group Inc logo Some data Nov 6, 2026

MiMedx Group Inc

MDXG · US
Undervalued, but in a downtrend

The stock costs 55% less than our calculation considers fair.

Fair value $7.32 · Strongly undervalued
Quality 69/100
Healthy Growth (revenue 5y +11.0 %/yr in USD)
Low debt
Generates free cash flow
Ranks above peers (8/13)
Even on cautious assumptions the value is 66% above the price ($5.49).
Thin margins · 1.8% net margin (TTM)
Moderate moat 45/100
Some data
Watch MiMedx Group Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$15.83 $2.63 Fair Value $7.32 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $2.63 – $15.83 · fair‑value band $5.49 – $9.48 · the $3.31 price screens below the $7.32 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow MiMedx Group in your weekly email

Every Wednesday you see whether MiMedx Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.

Show moreShow less

The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors.

Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization.

The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste.

Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions.

The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States.

The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.

Stock analysis

MiMedx Group Inc (MDXG) currently trades at $3.31, while our model-based Fair Value estimate is $7.32, implying the stock looks roughly 55% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $9.84 per share, and 22 of the 24 models we run sit above the $3.31 price.

Bear case: the Asset-Based group reads lowest at $1.31, and 2 of the 24 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $5.49 (bear) to $9.48 (bull), the price of $3.31 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

MiMedx Group Inc reported revenue of $419M in FY2025 versus $242M in FY2021, a compound +14.7%/yr. Reported net income was $48.6M in FY2025.

Key figures

Market cap $494M Small · P/S ratio 1.63 · EPS (TTM) $−0.1300 · Net margin 11.6% · Return on equity 2.9% · Return on assets (EBIT) 8.8% (5-year average) · Operating margin −28.7% · Revenue (TTM) $355M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (medium confidence).

What moves the price

The share trades about 57% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 121%, MDXG screens cheaper than that median.

Fair Value models

Bear $5.49 Fair Value $7.32 Bull $9.48
Price $3.31 · Upside +121.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $6.40 $10.28 $16.82 79
Growth DCF $6.25 $9.61 $14.50 78
Owner Earnings $3.97 $6.19 $9.69 75
All 24 models by family
DCF Models
FCF DCF $6.40 $10.28 $16.82 79
Owner Earnings $3.97 $6.19 $9.69 75
5Y Revenue Exit $5.50 $8.79 $13.33 72
5Y EBITDA Exit $6.31 $10.54 $15.98 74
5Y P/E Exit $6.20 $10.32 $15.17 70
10Y Revenue Exit $5.66 $8.75 $13.62 66
10Y EBITDA Exit $6.25 $9.91 $15.68 67
10Y P/E Exit $6.19 $9.76 $15.05 63
Earnings-Based
Graham-Dodd $2.26 $12.28 $17.03 63
Lynch FV $3.41 $4.87 $6.33 61
PEG = 1.0 $3.41 $4.87 $6.33 57
EPV $3.42 $3.73 $3.98 74
Multiples
P/E Multiple $5.49 $7.32 $9.15 63
P/S Multiple $4.24 $5.66 $7.07 58
P/B Multiple $5.16 $6.87 $8.59 55
EV/EBIT $6.57 $8.43 $10.29 66
EV/EBITDA $6.65 $8.54 $10.43 67
EV/Revenue $4.97 $6.68 $8.38 54
Asset-Based
NCAV (Graham) $0.8700 $1.31 $1.64 55
Growth DCF
Growth DCF $6.25 $9.61 $14.50 78
Rev-Margin DCF $5.50 $8.71 $13.08 72
Economic Profit
Residual Income $1.80 $2.38 $3.68 69
ROIC Compounder $3.68 $4.31 $5.02 72
Growth Earnings
Growth-Adj P/E $5.10 $7.29 $9.48 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 69/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 79
How much profit the company makes from its sales and capital
Quality Growth 45
Are margins and returns getting better?
Cashflow 77
Do the profits arrive as real cash?
Financial strength 99
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 42
How calm the share price moves, does not count
Price momentum 16
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 86
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 7 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 83/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+20.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
Start year 2020 (pandemic). Over 10 years: +8.4% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+51.9%
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−11.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−11.1%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−18% → 15%

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−13.4%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
−1.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −15.5% a year for the price and −3.3% for the forecasts.
Forecast 2026 (sales)−36.2%
Forecast 2027 (sales)+12.4%
Projected 2028 (sales)+11.1%
Projected 2029 (sales)+9.8%
Projected 2030 (sales)+8.5%

Watch MDXG, get fair value alerts →

Compare MiMedx Group Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 69 · Top 25%
Fair Value upside +121.1% · Top 25%
Profitability
Return on equity (12 months) 2.9% · Above median
Return on assets 14.2% · Top 25%
Net margin (12 months) 1.8% · Below median
Operating margin (12 months) −28.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −34.7% · Bottom 25%
Balance sheet
Debt / equity 0.06× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.93× · Cheaper than median
P/S (12 months) 1.39× · Cheapest 25%
Price / free cash flow (fiscal year) 6.8× · Cheapest 25%
EV/EBITDA 16.9× · Cheaper than median
PEG 2.88× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)12 · sector 0
HEALTH (low debt)97 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs MDXG
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs MDXG
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs MDXG
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs MDXG
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs MDXG
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs MDXG
argenx SE ARGX $927.21 $908.40 −2% vs MDXG
CSL Limited CSL A$200.77 A$183.04 −9% vs MDXG
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs MDXG
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs MDXG

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

MiMedx Group Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "MiMedx Group Inc Fair Value". https://www.fairvalue-calculator.com/stock/MDXG

Frequently asked questions

Is MiMedx Group Inc (MDXG) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $7.32 versus a price of $3.31, about +121% upside (undervalued).
What is the fair value of MDXG?
Our model-based fair value for MiMedx Group Inc is $7.32 (as of Nov 6, 2026), built from audited fundamentals. The current price: $3.31.
What is the quality score of MDXG?
MiMedx Group Inc has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MiMedx Group Inc (MDXG)?
Our model-based price target is the fair value of $7.32 (as of Nov 6, 2026) from 24 valuation models. Cautious scenario $5.49, optimistic scenario $9.48. It is a calculation from audited fundamentals, not an analyst target.
What is the MiMedx Group Inc stock forecast for 2026?
Our models put fair value at $7.32, about +121% upside versus a price of $3.31 (undervalued). Cautious scenario $5.49, optimistic scenario $9.48. The calculation is refreshed regularly with new filings.
What is the revenue of MiMedx Group Inc (MDXG)?
MiMedx Group Inc reported trailing-twelve-month revenue of about $355M (latest available figure, as of Nov 6, 2026).
What growth is priced into MiMedx Group Inc (MDXG)?
For today's price to be fair in a discounted-cash-flow model, MiMedx Group Inc would have to grow free cash flow by -13.4 % per year for five years (discount rate 11.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.0 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of MDXG use?
Our models discount MiMedx Group Inc at 11.7 %: a base by market capitalisation (small), damped by beta 1.17, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For MiMedx Group Inc that is -13.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.7 %) and the same formula as our fair value.
How much growth has MiMedx Group Inc (MDXG) delivered so far?
Over the past 5 years revenue at MiMedx Group Inc grew +11.0 % a year. The price currently implies free-cash-flow growth of -13.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of MiMedx Group Inc (MDXG) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into MiMedx Group Inc (-13.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of MiMedx Group Inc (MDXG)?
The free-cash-flow yield on the price is 14.92 %: that much free cash flow MiMedx Group Inc produces per unit of market value. When it exceeds the discount rate of our models (11.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of MiMedx Group Inc (MDXG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MiMedx Group Inc it is $7.32 per share (as of Nov 6, 2026), against a price of $3.31. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is MiMedx Group Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, MDXG trades below its calculated fair value: price $3.31, fair value $7.32, a gap of about +121% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MDXG?
No. The price is what the market pays today ($3.31); the fair value is what the company's own numbers justify ($7.32). For MiMedx Group Inc the two are $4.01 per share apart. That gap is exactly why we show both numbers side by side.
How much is MiMedx Group Inc worth?
The market values MiMedx Group Inc at about $494M (market capitalisation, as of Nov 6, 2026). Per share that is $3.31; our models calculate a fair value of $7.32 per share.
What do the bullish and bearish scenarios say about MDXG?
Our models span a range for MiMedx Group Inc: cautious scenario $5.49, base $7.32, optimistic $9.48 per share (as of Nov 6, 2026, price $3.31). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of MDXG?
The PEG ratio of MiMedx Group Inc is 2.88 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of MiMedx Group Inc (MDXG)?
Balance-sheet figures for MiMedx Group Inc (as of Nov 6, 2026): return on equity 2.9%, debt of 0.06 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is MDXG from its 52-week high?
MiMedx Group Inc trades at $3.31, about 57% below its 52-week high of $7.71 and 7% above the low of $3.09 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $7.32 is for.
Which stocks are comparable to MiMedx Group Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MiMedx Group Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $3.31, calculated fair value $7.32 (+121%), Quality Score 69/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MDXG calculated?
We run MiMedx Group Inc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $7.32 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. MiMedx Group Inc currently trades 55% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MiMedx Group Inc (MDXG)?
The closing price on Nov 6, 2026 was $3.31. Our model-based fair value is $7.32, about +121% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MiMedx Group Inc right now?
The price is below even our cautious bear case ($5.49). The market is more pessimistic than our downside scenario. Solid quality (69/100) at a price below fair value, the discount is the argument here, not the business quality.
Where does the earnings growth of MiMedx Group Inc (MDXG) come from?
Earnings per share at MiMedx Group Inc grew +10.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share +4.7 %, EBIT margin +10.7 %, tax rate +0.7 %, residual (interest, one-offs) −5.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of MiMedx Group Inc

How large is the market capitalisation of MiMedx Group Inc (MDXG)?
The market capitalisation of MiMedx Group Inc is $494M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MiMedx Group Inc (MDXG)?
The price-to-sales ratio of MiMedx Group Inc is 1.63 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of MiMedx Group Inc (MDXG)?
Earnings per share at MiMedx Group Inc are $−0.1300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of MiMedx Group Inc (MDXG)?
The net margin of MiMedx Group Inc is 11.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MiMedx Group Inc (MDXG)?
The return on equity (ROE) of MiMedx Group Inc is 2.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MiMedx Group Inc (MDXG)?
On an EBIT basis the return on assets of MiMedx Group Inc is 8.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MiMedx Group Inc (MDXG)?
The operating margin of MiMedx Group Inc is −28.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MiMedx Group Inc (MDXG)?
Revenue at MiMedx Group Inc is growing −34.7% versus a year earlier (3y avg +16.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at MiMedx Group Inc (MDXG)?
Earnings per share at MiMedx Group Inc are growing +99.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does MiMedx Group Inc (MDXG) hold?
MiMedx Group Inc holds more cash than debt, $144M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch MiMedx Group Inc in the live analysis

One click puts MiMedx Group Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.